How IPO-bound Gland Pharma’s valuation spiked under China’s Fosun
Advertisement

How IPO-bound Gland Pharma’s valuation spiked under China’s Fosun

By Ankit Doshi

  • 13 Jul 2020
Premium
How IPO-bound Gland Pharma’s valuation spiked under China’s Fosun
Credit: Reuters

China’s Shanghai Fosun Pharmaceutical Group, which acquired a majority stake in Gland Pharma Ltd less than three years ago,...

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.
Advertisement
Advertisement
Google News Icon

Google News

Follow VCCircle on Google News for the latest updates on Business and Startup News